Save
esh.org
Myeloma Hub
ESH eLearning, ESH , 204612
iCMLf Prize talk
ESH eLearning, Jerry Radich, 205141
John Goldman Prize Talk
ESH eLearning, Tim Hughes, 205140
Janet Rowley Prize talk
ESH eLearning, Mhairi Copland, 205142
Targeting non-coding RNAs in leukemia
ESH eLearning, Ramiro Garzon, 204647
Exportin (XPO1) inhibitors for the treatment of AML
ESH eLearning, Ramiro Garzon, 204648
Novel targets for AML
ESH eLearning, Ramiro Garzon, 204649
The spliceosome mutations that can cause hematological malignancies
ESH eLearning, Omar Abdel-Wahab, 204650
Efficacy of first generation FLT3 inhibitors for AML
ESH eLearning, Miguel Sanz, 204651
The need for collaboration amongst hospitals: learning from RATIFY
ESH eLearning, Miguel Sanz, 204652
Why are new molecules typically combined with standard chemotherapy?
ESH eLearning, Miguel Sanz, 204653
Integrating midostaurin into FLT3 positive AML treatment
ESH eLearning, Miguel Sanz, 204654
Role of genetics in hematological malignancies: expanding our understanding
ESH eLearning, Jane Churpek, 204655
Combinations with FLT3 inhibitors: the way forward for AML treatment
ESH eLearning, Katherine Smith, 204656
Resistance mechanisms to FLT3 inhibitors in AML
ESH eLearning, Katherine Smith, 204657
Infrastructure for AML treatment in Spain
ESH eLearning, Jorge Sierra, 204658
Finding novel treatment options for relapsed/progressing AML
ESH eLearning, Jorge Sierra, 204659
The importance of collaboration in AML research
ESH eLearning, Omar Abdel-Wahab, 204660
Neomorphic mutations driving hematological cancers
ESH eLearning, Omar Abdel-Wahab, 204661
Therapeutics targeting splicing in hematological malignancies
ESH eLearning, Omar Abdel-Wahab, 204662
What are the drivers of leukemia?
ESH eLearning, Omar Abdel-Wahab, 204663
The benefits of patient advocacy groups
ESH eLearning, Jane Churpek, 204664
Developing an understanding of disease progression in MDS and AML
ESH eLearning, Jane Churpek, 204665
Balancing hereditary research with patient care in leukemia
ESH eLearning, Jane Churpek, 204666
Combination therapies and improving overall survival in AML
ESH eLearning, Mark Levis, 204667
The challenges of using kinase inhibitors for AML treatment
ESH eLearning, Mark Levis, 204668
Venetoclax for elderly AML patients
ESH eLearning, Mark Levis, 204669
The drugs being used to treat newly diagnosed AML patients
ESH eLearning, Mark Levis, 204670
AML immunotherapy: patients need to be well informed
ESH eLearning, Marion Subklewe, 204671
The rapid progression of IDH1/2 mutant enzyme inhibitors through clinical trials
ESH eLearning, Stéphane , 204672
Advising AML patients to participate in clinical trials
ESH eLearning, Marina Konopleva, 204673
One size does not fit all: AML subtype treatment approaches
ESH eLearning, Mark Levis, 204674
AML immunotherapy: pre-clinical data to look forward to at ASH 2017
ESH eLearning, Marion Subklewe, 204675
AML clinical trials: early stage vs. relapse/refractory patients
ESH eLearning, Marion Subklewe, 204676
T-cell engaging antibodies: what lessons have we learnt?
ESH eLearning, Marion Subklewe, 204677
Upcoming clinical trials for venetoclax chemotherapy combinations for AML
ESH eLearning, Marina Konopleva, 204678
Providing the relevant information to patients: a changing approach in Spain
ESH eLearning, Jorge Sierra, 204679
What are the alternative treatment options for relapsed or elderly AML patients?
ESH eLearning, Jorge Sierra, 204680
Cytokine release syndrome: a limiting factor for AML treatment
ESH eLearning, John DiPersio, 204681
Bispecific agents: the future of AML and MDS treatment?
ESH eLearning, John DiPersio, 204682
The problem of treating AML with CD123-targeting drugs
ESH eLearning, John DiPersio, 204683
Mimetics: the future of AML treatment?
ESH eLearning, Andrew Wei, 204684
Highly targeted medication for AML
ESH eLearning, Andrew Wei, 204685
Combating AML
ESH eLearning, Andrew Wei, 204686
Current research into pro-apoptosis medication for leukemia
ESH eLearning, Andrew Wei, 204687
The molecular mechanisms of epigenetic therapies: LTRs and TINATs
ESH eLearning, Christoph Plass, 204688
The potential benefits of epigenetic therapy research
ESH eLearning, Christoph Plass, 204689
GATA2 and its influence on AML
ESH eLearning, Emery Bresnick, 204690
Collaboration and cooperation in hematology-oncology research
ESH eLearning, Emery Bresnick, 204691
The use of second generation FLT3 inhibitors for AML
ESH eLearning, Francesco Lo-Coco, 204692
The standardization of molecular diagnostics for myeloid diseases in Italy
ESH eLearning, Francesco Lo-Coco, 204693
New treatments for AML using inhibitors
ESH eLearning, Francesco Lo-Coco, 204694
The future of leukemia treatment in the elderly
ESH eLearning, John DiPersio, 204695
When to use bispecifics for AML
ESH eLearning, John DiPersio, 204696
Expanding trials using bispecifics
ESH eLearning, John DiPersio, 204697
The challenges facing elderly AML treatment
ESH eLearning, Lars Bullinger, 204698
Adapting AML treatment for elderly patients
ESH eLearning, Lars Bullinger, 204699
Translational research in Berlin to improve AML treatment outcomes
ESH eLearning, Lars Bullinger, 204700
Reassuring patients with AML
ESH eLearning, Lars Bullinger, 204701
Selecting AML patients for intensive treatment
ESH eLearning, Marina Konopleva, 204702
Promising results for venetoclax combination therapies in elderly AML
ESH eLearning, Marina Konopleva, 204703
An overview of immunotherapies for leukemia
ESH eLearning, Ravindra Majeti, 204704
Tackling CD47-positive malignancies
ESH eLearning, Ravindra Majeti, 204705
Pre-leukemic stem cells: a telltale sign of AML
ESH eLearning, Ravindra Majeti, 204706
Game-changing treatments for leukemia
ESH eLearning, Ravindra Majeti, 204707
CAR T-cells and CRISPR: The future of AML treatment
ESH eLearning, Saar Gill, 204708
The development of novel treatment modalities: regulations and expectations
ESH eLearning, Saar Gill, 204709
Transferring lessons learnt from treating ALL to AML
ESH eLearning, Saar Gill, 204710
Price vs. performance: CAR T-cells
ESH eLearning, Saar Gill, 204711
The potential of differentiation therapies for AML
ESH eLearning, Stéphane de Botton, 204712
The next steps for the IDH2 inhibitor drug enasidenib
ESH eLearning, Stéphane de Botton, 204713
Working with smaller research companies
ESH eLearning, Stéphane de Botton, 204714
The future of AML and MDS diagnosis and treatment
ESH eLearning, Stéphane de Botton, 204715
New generation studies in follicular and mantle cell lymphoma in the US National Clinical Trials Network (NCTN)
ESH eLearning, Little Richard, 202162
European Mantle Cell Network
ESH eLearning, Dreyling Martin, 202163
Activities of the NCRI and UK lymphoma studies
ESH eLearning, Collins Graham, 202164
MRD in CLL
ESH eLearning, Rawstron Andy, 202155
Initial diagnostic work up of MCL
ESH eLearning, Dreyling Martin, 202156
Status of allogeneic transplant immunotherapy compared to CAR T cells (a comparative analysis)
ESH eLearning, Maloney David, 202157
Immune checkpoint inhibitors in indolent lymphomas
ESH eLearning, Ansell Stephen, 202158
BCL2 & regulation of the apoptotic response in lymphoid
ESH eLearning, Letai Anthony, 202159
Targeting BTK in current therapy of indolent NHL and CLL
ESH eLearning, Maddocks Kami J., 202160
Novel inhibitors in lymphoma – an outlook
ESH eLearning, Niemann Carsten U., 202161
Genomic landscape of CLL and other indolent lymphoma
ESH eLearning, Cathy Wu, 202147
Routes of transformation of follicular lymphoma
ESH eLearning, Fitzgibbon Jude, 202148
Next generation sequencing data analysis: critical issues
ESH eLearning, Reinhardt Christian, 202149
CLL microenvironment as a drug target for kinase inhibitors
ESH eLearning, Burger Jan, 202150
Modulation of the TME in NHL
ESH eLearning, Wiestner Adrian, 202151
Epigenetic basis of germinal center derived B Cell lymphomas
ESH eLearning, Melnick Ari, 202152
Disparity of lymphoma treatment in South America
ESH eLearning, Gabus Raul, 202153
Potential disparities in Europe
ESH eLearning, Michael Hallek, 202154
No treatment is no option for plasma cell leukaemia?
ESH eLearning, Niels van de Donk, 188656
Treatment of Castleman: monoclonal antibodies or chemotherapy ?
ESH eLearning, Angela Dispenzieri, 188657
Amyloidosis: from proteomics to resolving proteins
ESH eLearning, Giampolo Merlini, 188658
From the start ?
ESH eLearning, Bart Barlogie, 188659
Later on ?
ESH eLearning, Philippe Moreau, 188660
First line treatment of Tx non-eligible patients from fit to frail
ESH eLearning, Sonja Zweegman, 188652
Treatment of high risk Multiple Myeloma: should we treat them differently ?
ESH eLearning, Philippe Moreau, 188653
Treatment of refractory disease
ESH eLearning, Meletios A Dimopoulos, 188654
Allogeneic stem cell transplantation: when and who ?
ESH eLearning, Shaji K Kumar, 188655